Literature DB >> 21287692

TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks.

Nazneen Fatima1, Cynthia Cohen, Diane Lawson, Momin T Siddiqui.   

Abstract

BACKGROUND: Immunohistochemistry (IHC) for thyroid transcription factor-1 (TTF-1) is used to confirm the diagnosis of lung adenocarcinoma. Napsin A also has shown positivity in lung adenocarcinoma. A combined double stain for TTF-1 and napsin A has been proposed to achieve higher sensitivity and specificity. In this study, the authors evaluated the utility of this double stain in the diagnosis of lung adenocarcinoma in cell blocks of fine-needle aspirates (FNA).
METHODS: The authors used a cohort comprising 35 FNA cell blocks of lung adenocarcinoma and 24 FNA cell blocks of lung squamous cell carcinoma (SqCCA). IHC was performed; expressions of TTF-1 as brown nuclear stain and of napsin A as red cytoplasmic stain were identified.
RESULTS: Twenty-six of 35 (74%) lung adenocarcinomas were positive for double staining with TTF-1/napsin A. Of 35 lung adenocarcinomas, only 2 (5%) were positive for TTF-1 alone and 3 (8%) were positive for napsin A alone. For the double stain TTF-1/napsin A, 3 of 24 (12%) lung SqCCAs were positive for both. Six of 24 (25%) cases were positive for TTF-1 alone, and none were positive for napsin A alone. For lung adenocarcinoma, TTF-1/napsin A has a sensitivity of 74%, specificity of 87%, accuracy of 79%, and a positive predictive value of 89%.
CONCLUSIONS: The double IHC stain, TTF-1/napsin A, for the identification of pulmonary adenocarcinoma in FNA cell block materials was diagnostically useful. The use of napsin A alone demonstrated a greater degree of accuracy and appeared diagnostically useful as a single IHC stain.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287692     DOI: 10.1002/cncy.20135

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  17 in total

Review 1.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

Authors:  Lais Osmani; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Semin Cancer Biol       Date:  2017-11-26       Impact factor: 15.707

2.  Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim Geisinger; Yasushi Yatabe; Yuichi Ishikawa; Ignacio Wistuba; Douglas B Flieder; Wilbur Franklin; Adi Gazdar; Philip S Hasleton; Douglas W Henderson; Keith M Kerr; Iver Petersen; Victor Roggli; Erik Thunnissen; Ming Tsao
Journal:  Arch Pathol Lab Med       Date:  2012-09-12       Impact factor: 5.534

3.  Downregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case report.

Authors:  Masatoshi Takagaki; Manabu Kinoshita; Kazumi Nishino; Masakazu Nakano; Hiroko Adachi; Morio Ueno; Masanori Kitamura; Yasunori Fujimoto; Kei Tashiro; Yasuhiko Tomita; Fumio Imamura; Toshiki Yoshimine
Journal:  Oncol Lett       Date:  2017-02-06       Impact factor: 2.967

4.  The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.

Authors:  Ming-Hui Ao; Hui Zhang; Lynne Sakowski; Rajni Sharma; Peter B Illei; Edward Gabrielson; Frederic Askin; Qing Kay Li
Journal:  Hum Pathol       Date:  2014-01-25       Impact factor: 3.466

5.  Warranting investigation of primary lung adenocarcinoma in patients with an extrapulmonary malignancy and lung nodules due to high frequency.

Authors:  Bing Zhu; Shavari Dalal; David W Kamp; Xiaoqi Lin
Journal:  Am J Clin Pathol       Date:  2014-03       Impact factor: 2.493

6.  Ancillary testing in lung cancer diagnosis.

Authors:  William Dubinski; Natasha B Leighl; Ming-Sound Tsao; David M Hwang
Journal:  Pulm Med       Date:  2012-01-04

7.  Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.

Authors:  Grzegorz T Gurda; Lei Zhang; Yuting Wang; Li Chen; Susan Geddes; William C Cho; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Clin Transl Med       Date:  2015-04-21

8.  Primary signet ring cell carcinoma of the lung with cerebellar metastasis showing full response to Cisplatin and docetaxel therapy.

Authors:  Onur Kocas; Fatih Selcukbiricik; Ahmet Bilici; Metin Kanıtez; Serdar Yildiz; Suna Avci; Canan Tanik
Journal:  Case Rep Oncol Med       Date:  2014-01-09

9.  Dual color multiplex TTF-1 + Napsin A and p63 + CK5 immunostaining for subcategorizing of poorly differentiated pulmonary non-small carcinomas into adenocarcinoma and squamous cell carcinoma in fine needle aspiration specimens.

Authors:  Seema Sethi; Lili Geng; Vinod B Shidham; Pamela Archuletta; Sudeshna Bandyophadhyay; Jining Feng; Shashi Madan; Dongping Shi; Paul Tranchida; Tamar Giorgadze
Journal:  Cytojournal       Date:  2012-03-31       Impact factor: 2.091

Review 10.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.